Hepatocellular Carcinoma (HCC)Phase 2NCT07128251
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
A Phase 2 study testing TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) and Bevacizumab in people with Hepatocellular Carcinoma (HCC) and Immunotherapy, run by Anhui Provincial Hospital.
Trial summary
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1
- What is being tested?
- TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) and Bevacizumab
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- No sites listed yet
- Study dates
- 20 Aug 2025to 30 Dec 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily participate in the study and provide written informed consent.
- Age 18-75 years, inclusive (male or female).
- Histologically or cytologically confirmed HCC, or clinically diagnosed HCC according to the *Clinical Practice Guidelines for Primary Liver Cancer (2024 Edition)*.
- Barcelona Clinic Liver Cancer (BCLC) Stage A, B, or C, not amenable to curative treatment (e.g., surgical resection, liver transplantation, or ablation).
- At least one measurable lesion according to RECIST v1.1 criteria.
- Suitable candidate for Transarterial Chemoembolization (TACE) with no known allergy or contraindication to iodized oil or epirubicin.
Show all 13Show fewer
- Child-Pugh Liver Function Class A.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Life expectancy ≥ 3 months.
- Adequate organ and bone marrow function.
- If positive for Hepatitis B Virus (HBV) infection, HBV DNA must be < 2000 IU/mL (< 10,000 copies/mL if only copies/mL units available at the site) and the subject must be willing to receive continuous antiviral therapy throughout the study period. Subjects positive for Hepatitis C Virus (HCV) RNA must receive antiviral therapy according to clinical guidelines.
- Subjects with esophageal/gastric varices must undergo evaluation and appropriate management prior to enrollment.
- Women of childbearing potential (WOCBP): Must have a negative serum human chorionic gonadotropin (hCG) test within 7 days prior to initiation of study treatment; must be non-lactating; must agree to use highly effective contraception methods from signing informed consent until 120 days after the last dose of study treatment. A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy/oophorectomy). Male subjects with female partners of childbearing potential: Must agree to use highly effective contraception methods from signing informed consent until 120 days after the last dose of study treatment; must agree to refrain from sperm donation. Male subjects with pregnant partners must use condoms; no additional contraception is required.
Who cannot join
- Known fibrolamellar HCC, sarcomatoid HCC, mixed hepatocellular cholangiocarcinoma, or cholangiocarcinoma; history of other active malignancies within 5 years or concurrently with HCC. Cured localized tumors (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma *in situ* of the prostate, cervix, or breast) are permitted.
- Presence of Vp3 or Vp4 portal vein tumor thrombosis (PVTT), any grade of hepatic vein or inferior vena cava invasion; any grade of bile duct invasion. *Note: Vp1 or Vp2 PVTT is permitted.*
- Presence of extrahepatic spread (EHS).
- Intrahepatic lesion(s) with maximum diameter ≥ 10 cm, > 10 intrahepatic lesions, or intrahepatic tumor burden ≥ 70% of liver volume, per RECIST v1.1.
- Prior systemic anti-cancer therapy for HCC, including molecular targeted agents, cytotoxic chemotherapy, immunotherapy (e.g., immune checkpoint inhibitors, immune checkpoint agonists, cellular therapies), or biologic therapy (e.g., cancer vaccines, cytokines, growth factors).
- Prior locoregional therapy for HCC, including therapeutic TACE, transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), transarterial radioembolization (TARE).
Show all 23Show fewer
- 1) Prior curative surgery or ablation is permitted; one session of prophylactic TACE following curative resection is permitted.
- 2) Prior percutaneous ethanol injection (PEI) or radiotherapy with curative intent is permitted.
- 7. Prior or planned organ transplantation or allogeneic bone marrow transplantation.
- 8. Current interstitial lung disease (ILD)/pneumonitis, history of ILD/pneumonitis requiring steroid treatment, or other pulmonary conditions that may interfere with the detection or management of immune-mediated pneumonitis (e.g., pulmonary fibrosis, organizing pneumonia [e.g., bronchiolitis obliterans], pneumoconiosis, drug-induced pneumonitis, idiopathic pneumonitis, or active pneumonia evidenced by screening chest computed tomography [CT] scan). Prior radiation pneumonitis within the radiation field is permitted. Active tuberculosis.
- 9. Active autoimmune disease or history of autoimmune disease with potential for recurrence (e.g., autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; subjects with hypothyroidism stable on hormone replacement are eligible). Conditions not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia), controlled Type I diabetes on insulin, or childhood asthma in complete remission without adult intervention are permitted. Asthma requiring bronchodilator therapy is excluded.
- 10. Clinically significant ascites requiring therapeutic paracentesis or drainage (Child-Pugh score >2 for ascites; asymptomatic ascites detected only radiographically is permitted); uncontrolled or moderate/large pleural effusion or pericardial effusion.
- 11. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg based on ≥2 measurements) despite antihypertensive therapy; history of hypertensive crisis or hypertensive encephalopathy.
- 12. Clinically significant cardiac disease. 13. History of spontaneous rupture of hepatic tumor(s). 14. History of hepatic encephalopathy. 15. History or presence of central nervous system metastases. 16. Congenital or acquired immunodeficiency (e.g., HIV infection). 17. Thromboembolic event within 3 months prior to treatment (e.g., cerebrovascular accident [including transient ischemic attack, cerebral hemorrhage, cerebral infarction], deep vein thrombosis, pulmonary embolism).
- 18. History of gastrointestinal (GI) bleeding within 6 months prior to treatment or high risk of GI bleeding (e.g., high-risk or severe esophageal/gastric varices, active GI ulceration, persistent fecal occult blood positivity). Note: If fecal occult blood positive at baseline, repeat test; if persistently positive, esophagogastroduodenoscopy [EGD] required; exclusion if EGD shows varices/lesions with bleeding risk. 19. Abdominal fistula, GI perforation, intra-abdominal abscess, or bowel obstruction within 6 months prior to treatment.
- 20. Major surgical procedure within 4 weeks prior to treatment or anticipated during study; unhealed wound, ulcer, or fracture within 4 weeks prior to treatment.
- 21. Coagulopathy or bleeding diathesis (e.g., hemophilia); use of antiplatelet agents (e.g., aspirin >325 mg/day, dipyridamole, ticlopidine, clopidogrel, cilostazol) or anticoagulants (e.g., warfarin, low molecular weight heparin) within 10 days prior to treatment.
- 22. Significant vascular disease within 6 months prior to treatment (e.g., aortic aneurysm requiring surgical repair, recent peripheral arterial thrombosis).
- 23. Severe infection within 4 weeks prior to treatment (e.g., requiring hospitalization for infection, bacteremia, or severe pneumonia complications); therapeutic antibiotics administered orally or intravenously within 2 weeks prior to treatment (prophylactic antibiotics, e.g., for UTI or COPD prevention, are permitted).
- 24. Known hypersensitivity to the active substances or excipients of Iparomlimab and Tuvonralimab Injection, Bevacizumab Injection, or epirubicin; history of severe hypersensitivity to any other monoclonal antibody or anti-angiogenic targeted therapy.
- 25. Use of immunosuppressive agents or systemic corticosteroids (>10 mg/day prednisone or equivalent) for immunosuppressive purposes within 2 weeks prior to treatment.
- 26. Administration of live attenuated vaccines within 4 weeks prior to treatment or planned during Iparomlimab and Tuvonralimab Injection treatment or within 60 days after the last dose.
- 27. Treatment with any investigational agent within 4 weeks or 5 half-lives (whichever is longer) prior to treatment initiation.Subjects with any other condition deemed by the investigator to potentially affect study results or lead to premature study termination (e.g., alcoholism, drug abuse, other severe medical/psychiatric disorders requiring concomitant therapy, significant laboratory abnormalities, or familial/societal factors compromising subject safety).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
Read the detailed description
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
After signing the informed consent form (ICF) and passing screening, subjects will undergo the first TACE procedure. Conventional TACE (cTACE) will be performed using lipiodol as the embolic agent and epirubicin as the chemotherapeutic agent. Study drug administration will commence at least 2 weeks after the first TACE: Iparomlimab and Tuvonralimab Injection [7.5 mg/kg, intravenous infusion, Day 1 (D1) of each cycle, every 21 days (Q3W)] combined with Bevacizumab Injection [15 mg/kg, intravenous infusion, D1, Q3W]. Each treatment cycle is 21 days (Q3W). On-demand TACE therapy will be administered concurrently, with a maximum of 4 TACE sessions permitted. The interval between consecutive TACE sessions must be at least 4 weeks. Bevacizumab Injection must be withheld for at least 2 days prior to any TACE procedure. Study drug administration must resume at least 2 weeks after any TACE procedure. Subjects must have fully recovered from TACE prior to receiving study drugs. Investigators may delay dosing based on toxicity recovery, but study drugs should be administered as soon as feasible once requirements are met.
Treatment will continue until the investigator assesses no further clinical benefit for the subject, the subject experiences intolerable toxicity, withdraws consent, or meets other protocol-specified criteria for treatment discontinuation (whichever occurs first).
Safety Visits: After enrollment, safety assessments will be performed 2 weeks (14 ± 3 days) after each TACE procedure and on D1 of each study drug cycle prior to drug administration. Subjects will continue safety assessments and survival follow-up after treatment completion.
Safety Reporting Period: Starts from the first TACE treatment and ends 90 days after the last dose of Iparomlimab and Tuvonralimab Injection [non-serious adverse events (AEs) unrelated to study drugs are collected only until 30 days after the last dose], or 30 days after the last dose of Bevacizumab Injection, or 30 days after the last TACE procedure, whichever is later.
Survival Follow-up: After the safety visit period, survival status and subsequent anti-tumor therapies will be collected every 12 weeks (±7 days) via clinical or telephone follow-up until subject death, loss to follow-up, sponsor study termination, or other study completion criteria are met (whichever occurs first).
- Conditions
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4, TACE
- Being tested
- TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab
- Medical subject headings
- Carcinoma, Hepatocellular, Diabetes Mellitus, Insulin-Dependent, 12
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TACE treatmentProcedure or surgery
TACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted.
Iparomlimab and Tuvonralimab Injection (QL1706)Drug
Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
BevacizumabDrug
Bevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
| Study group | Role | What they receive |
|---|---|---|
| experimental group | Experimental | TACE → Iparomlimab and Tuvonralimab Injection (QL1706) + Bevacizumab Injection (Q3W, 2 cycles). On-demand TACE therapy will be administered concurrently, with a maximum of 4 TACE sessions permitted. Receives: Procedure: TACE treatment; Drug: Iparomlimab and Tuvonralimab Injection (QL1706); Drug: Bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Defined as the time from initiation of study intervention to the first occurrence of either investigator-assessed (RECIST v1.1) radiographic disease progression or death from any cause.
Measured: 2-year
Secondary outcomes (4)
Objective Response Rate (ORR)
Proportion of subjects achieving Complete Response (CR) or Partial Response (PR) among all enrolled subjects (assessed by investigators per RECIST v1.1 and mRECIST).
Measured: 6-month
Disease Control Rate (DCR)
Proportion of subjects achieving CR, PR, or Stable Disease (SD) among all enrolled subjects (assessed by investigators per RECIST v1.1 and mRECIST)
Measured: 6-month
Overall Survival (OS)
Time from the start of therapy to death from any cause.
Measured: 3-year
Adverse event (AE)
Adverse events (AEs), Serious Adverse events (SAEs), surgery related safety.
Measured: 3-year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start20 Aug 2025 (estimated)
- Primary completion30 Jan 2028 (estimated)
- Study completion30 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 47 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Anhui Provincial Hospital
- Sponsor type
- Other government
- Collaborators
- Qilu Hospital of Shandong University, Henan Provincial People's Hospital, First Affiliated Hospital of Guangxi Medical University, Shanxi Province Cancer Hospital, Xi'an International Medical Center Hospital, The Second Affiliated Hospital of Harbin Medical University
- Responsible party
- Principal investigator, Lianxin Liu，PhD, Anhui Provincial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07128251
- Sponsor's protocol ID
- 2025KY309
- Status last verified
- Aug 2025
- First submitted
- 13 Aug 2025
- Last updated
- 17 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
- ClinicalTrials.gov ID
- NCT07128251
- Acronym / sponsor ID
- 2025KY309
- Conditions
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4, TACE
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 47 participants (estimated)
- Lead sponsor
- Anhui Provincial HospitalOther government
- Collaborators
- Qilu Hospital of Shandong University, Henan Provincial People's Hospital, First Affiliated Hospital of Guangxi Medical University, Shanxi Province Cancer Hospital, Xi'an International Medical Center Hospital, The Second Affiliated Hospital of Harbin Medical University
- Study start
- 20 Aug 2025 (estimated)
- Primary completion
- 30 Jan 2028 (estimated)
- Study completion
- 30 Dec 2029 (estimated)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
Detailed description
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
After signing the informed consent form (ICF) and passing screening, subjects will undergo the first TACE procedure. Conventional TACE (cTACE) will be performed using lipiodol as the embolic agent and epirubicin as the chemotherapeutic agent. Study drug administration will commence at least 2 weeks after the first TACE: Iparomlimab and Tuvonralimab Injection [7.5 mg/kg, intravenous infusion, Day 1 (D1) of each cycle, every 21 days (Q3W)] combined with Bevacizumab Injection [15 mg/kg, intravenous infusion, D1, Q3W]. Each treatment cycle is 21 days (Q3W). On-demand TACE therapy will be administered concurrently, with a maximum of 4 TACE sessions permitted. The interval between consecutive TACE sessions must be at least 4 weeks. Bevacizumab Injection must be withheld for at least 2 days prior to any TACE procedure. Study drug administration must resume at least 2 weeks after any TACE procedure. Subjects must have fully recovered from TACE prior to receiving study drugs. Investigators may delay dosing based on toxicity recovery, but study drugs should be administered as soon as feasible once requirements are met.
Treatment will continue until the investigator assesses no further clinical benefit for the subject, the subject experiences intolerable toxicity, withdraws consent, or meets other protocol-specified criteria for treatment discontinuation (whichever occurs first).
Safety Visits: After enrollment, safety assessments will be performed 2 weeks (14 ± 3 days) after each TACE procedure and on D1 of each study drug cycle prior to drug administration. Subjects will continue safety assessments and survival follow-up after treatment completion.
Safety Reporting Period: Starts from the first TACE treatment and ends 90 days after the last dose of Iparomlimab and Tuvonralimab Injection [non-serious adverse events (AEs) unrelated to study drugs are collected only until 30 days after the last dose], or 30 days after the last dose of Bevacizumab Injection, or 30 days after the last TACE procedure, whichever is later.
Survival Follow-up: After the safety visit period, survival status and subsequent anti-tumor therapies will be collected every 12 weeks (±7 days) via clinical or telephone follow-up until subject death, loss to follow-up, sponsor study termination, or other study completion criteria are met (whichever occurs first).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| experimental group | Experimental | Procedure: TACE treatment, Drug: Iparomlimab and Tuvonralimab Injection (QL1706), Drug: BevacizumabTACE → Iparomlimab and Tuvonralimab Injection (QL1706) + Bevacizumab Injection (Q3W, 2 cycles). On-demand TACE therapy will be administered concurrently, with a maximum of 4 TACE sessions permitted. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Voluntarily participate in the study and provide written informed consent.
- Age 18-75 years, inclusive (male or female).
- Histologically or cytologically confirmed HCC, or clinically diagnosed HCC according to the *Clinical Practice Guidelines for Primary Liver Cancer (2024 Edition)*.
- Barcelona Clinic Liver Cancer (BCLC) Stage A, B, or C, not amenable to curative treatment (e.g., surgical resection, liver transplantation, or ablation).
- At least one measurable lesion according to RECIST v1.1 criteria.
Key exclusion criteria (23 listed)
- Known fibrolamellar HCC, sarcomatoid HCC, mixed hepatocellular cholangiocarcinoma, or cholangiocarcinoma; history of other active malignancies within 5 years or concurrently with HCC. Cured localized tumors (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma *in situ* of the prostate, cervix, or breast) are permitted.
- Presence of Vp3 or Vp4 portal vein tumor thrombosis (PVTT), any grade of hepatic vein or inferior vena cava invasion; any grade of bile duct invasion. *Note: Vp1 or Vp2 PVTT is permitted.*
- Presence of extrahepatic spread (EHS).
- Intrahepatic lesion(s) with maximum diameter ≥ 10 cm, > 10 intrahepatic lesions, or intrahepatic tumor burden ≥ 70% of liver volume, per RECIST v1.1.
- Prior systemic anti-cancer therapy for HCC, including molecular targeted agents, cytotoxic chemotherapy, immunotherapy (e.g., immune checkpoint inhibitors, immune checkpoint agonists, cellular therapies), or biologic therapy (e.g., cancer vaccines, cytokines, growth factors).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TACE treatmentTACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted. | Procedure or surgery | experimental group |
| Iparomlimab and Tuvonralimab Injection (QL1706)Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. | Drug | experimental group |
| BevacizumabBevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. | Drug | experimental group |
Primary outcome
Progression-Free Survival (PFS) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Time frame: 2-year
Defined as the time from initiation of study intervention to the first occurrence of either investigator-assessed (RECIST v1.1) radiographic disease progression or death from any cause.
4 secondary outcomes
Objective Response Rate (ORR)
Time frame: 6-month
Disease Control Rate (DCR)
Time frame: 6-month
Overall Survival (OS)
Time frame: 3-year
Adverse event (AE)
Time frame: 3-year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma (HCC)
RecruitingPhase 2/3
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
HCC
Not yet recruitingObservational study
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
Hepatocellular Carcinoma (HCC)
Active, not recruitingPhase 2
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular Carcinoma
RecruitingPhase 1
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
RecruitingPhase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) and Bevacizumab in people with Hepatocellular Carcinoma (HCC) and Immunotherapy, run by Anhui Provincial Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lianxin Liu (0551-62283477, liulx@ustc.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (time frame: 2-year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.